Literature DB >> 2260699

Direct electrophysiological actions of pentobarbital at concentrations achieved during general anesthesia.

S Nattel1, Z G Wang, C Matthews.   

Abstract

Pentobarbital and alpha-chloralose are widely used for experimental anesthesia, but their direct electrophysiological actions at anesthetic concentrations are unknown. Trough and peak concentrations measured by high-performance liquid chromatography averaged 27 +/- 3 and 45 +/- 13 mg/l (means +/- SD) for pentobarbital and 41 +/- 15 and 103 +/- 13 mg/l for alpha-chloralose in dogs receiving them for general anesthesia. The direct effects of each agent on papillary muscle action potentials obtained from guinea pigs killed by decapitation were studied in vitro. Pentobarbital increased action potential duration to 95% by 24 +/- 6 and 33 +/- 4% at 25 and 50 mg/l (P less than 0.001 for each), respectively, and caused corresponding increases in effective refractory period. Furthermore, pentobarbital reduced maximum rate of voltage change (Vmax) of phase 0 in a voltage-, rate-, and concentration-dependent fashion, suggesting use-dependent sodium channel blocking actions. The voltage dependence of Vmax was shifted by 3.7 +/- 1.7 (P less than 0.01) and 6.5 +/- 1.8 mV (P less than 0.001) by 25 and 50 mg/l pentobarbital, respectively. In canine ventricular muscle, pentobarbital caused rate- and concentration-dependent decreases in Vmax and increases in action potential duration and refractory period over a concentration range of 5-100 mg/l. alpha-Chloralose was devoid of direct electrophysiological effects in both species. We conclude that pentobarbital has potentially important electrophysiological actions on ventricular tissues at concentrations required for general anesthesia and may confound the results of in vivo studies.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2260699     DOI: 10.1152/ajpheart.1990.259.6.H1743

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  8 in total

1.  The actions of ether, alcohol and alkane general anaesthetics on GABAA and glycine receptors and the effects of TM2 and TM3 mutations.

Authors:  M D Krasowski; N L Harrison
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

2.  In vivo temporal and spatial distribution of depolarization and repolarization and the illusive murine T wave.

Authors:  Gang Liu; Jason B Iden; Kay Kovithavongs; Rashida Gulamhusein; Henry J Duff; Katherine M Kavanagh
Journal:  J Physiol       Date:  2003-11-21       Impact factor: 5.182

3.  Resolving the M-cell debate: why and how.

Authors:  Stanley Nattel; Charles Antzelevitch; Denis Noble
Journal:  Heart Rhythm       Date:  2011-08       Impact factor: 6.343

4.  Effects of pentobarbital on inotropic state of isolated canine left ventricle.

Authors:  D S Snyder; Y Harasawa; K Sagawa; W C Hunter
Journal:  Heart Vessels       Date:  1993       Impact factor: 2.037

5.  Determinants of cardiac electrophysiological properties in mice.

Authors:  Gregory O Appleton; Yi Li; George E Taffet; Craig J Hartley; Lloyd H Michael; Mark L Entman; Robert Roberts; Dirar S Khoury
Journal:  J Interv Card Electrophysiol       Date:  2004-08       Impact factor: 1.900

6.  Relevance of anaesthesia for dofetilide-induced torsades de pointes in alpha1-adrenoceptor-stimulated rabbits.

Authors:  D Vincze; A S Farkas; L Rudas; P Makra; N Csík; I Leprán; T Forster; M Csanády; J G Papp; A Varró; A Farkas
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

Review 7.  Minimizing repolarization-related proarrhythmic risk in drug development and clinical practice.

Authors:  Attila S Farkas; Stanley Nattel
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

8.  The plateau outward current in canine ventricle, sensitive to 4-aminopyridine, is a constitutive contributor to ventricular repolarization.

Authors:  A Sridhar; D N Q da Cunha; V A Lacombe; Q Zhou; J J Fox; R L Hamlin; C A Carnes
Journal:  Br J Pharmacol       Date:  2007-08-13       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.